NeurAxis (NASDAQ:NRXS – Get Free Report) is one of 74 publicly-traded companies in the “Electromedical equipment” industry, but how does it compare to its peers? We will compare NeurAxis to related businesses based on the strength of its earnings, risk, profitability, institutional ownership, analyst recommendations, valuation and dividends.
Profitability
This table compares NeurAxis and its peers’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
NeurAxis | -594.55% | N/A | -899.27% |
NeurAxis Competitors | -333.03% | -41.70% | -24.26% |
Analyst Ratings
This is a breakdown of recent ratings and recommmendations for NeurAxis and its peers, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
NeurAxis | 0 | 0 | 1 | 0 | 3.00 |
NeurAxis Competitors | 227 | 714 | 1893 | 98 | 2.64 |
Insider & Institutional Ownership
11.8% of NeurAxis shares are held by institutional investors. Comparatively, 43.2% of shares of all “Electromedical equipment” companies are held by institutional investors. 15.5% of shares of all “Electromedical equipment” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Valuation & Earnings
This table compares NeurAxis and its peers gross revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
NeurAxis | $2.46 million | -$14.63 million | -0.65 |
NeurAxis Competitors | $964.46 million | $82.03 million | 6.30 |
NeurAxis’ peers have higher revenue and earnings than NeurAxis. NeurAxis is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.
Summary
NeurAxis peers beat NeurAxis on 9 of the 12 factors compared.
About NeurAxis
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
Receive News & Ratings for NeurAxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeurAxis and related companies with MarketBeat.com's FREE daily email newsletter.